CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells

Safely targeting cancer stem cells via selective catenin coactivator antagonism

(2014) Heinz-Josef Lenz et al.   CANCER SCIENCE

Can we safely target the WNT pathway?

(2014) Michael Kahn   NATURE REVIEWS DRUG DISCOVERY

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

(2013) E. Bolton-Gillespie et al.   BLOOD

Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options

(2013) Elias J. Jabbour et al.   Clinical Lymphoma Myeloma & Leukemia

Wnt/β-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours

(2013) Peter Wend et al.   EMBO JOURNAL

Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway

(2013) Kaijie He et al.   INTERNATIONAL JOURNAL OF CANCER

Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia

(2013) E J Gang et al.   ONCOGENE

Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability

(2012) Binfeng Xia et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML

(2012) Florian H. Heidel et al.   Cell Stem Cell

Human Embryonic Stem Cells Differentiated to Lung Lineage-Specific Cells Ameliorate Pulmonary Fibrosis in a Xenograft Transplant Mouse Model

(2012) Ena Ray Banerjee et al.   PLoS One

Wnt Signaling Orchestration with a Small Molecule DYRK Inhibitor Provides Long-Term Xeno-Free Human Pluripotent Cell Expansion

(2012) Kouichi Hasegawa et al.   Stem Cells Translational Medicine

Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia

(2011) E. Park et al.   BLOOD

The Gamma Catenin/CBP Complex Maintains Survivin Transcription in β-catenin Deficient/Depleted Cancer Cells

(2011) Y.-M. Kim et al.   CURRENT CANCER DRUG TARGETS

Symmetric division versus asymmetric division: a tale of two coactivators

(2011) Michael Kahn   Future Medicinal Chemistry

Targeted Inhibition of  -Catenin/CBP Signaling Ameliorates Renal Interstitial Fibrosis

(2011) S. Hao et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The Transcriptional Coactivator Cbp Regulates Self-Renewal and Differentiation in Adult Hematopoietic Stem Cells

(2011) W.-I. Chan et al.   MOLECULAR AND CELLULAR BIOLOGY

Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells

(2011) Faiyaz Notta et al.   NATURE

Neutrophil transmigration triggers repair of the lung epithelium via  -catenin signaling

(2011) R. L. Zemans et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

β-Catenin Mediates the Establishment and Drug Resistance of MLL Leukemic Stem Cells

(2010) Jenny Yeung et al.   CANCER CELL

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Molecular pathways to CML stem cells

(2010) Kristen N. Rice et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Genome-wide assessment of differential roles for p300 and CBP in transcription regulation

(2010) Y. F. M. Ramos et al.   NUCLEIC ACIDS RESEARCH

Preferential Induction of EphB4 over EphB2 and Its Implication in Colorectal Cancer Progression

(2009) S. R. Kumar et al.   CANCER RESEARCH

sFRP1 promoter methylation is associated with persistent Philadelphia chromosome in chronic myeloid leukemia

(2009) Melek Pehlivan et al.   LEUKEMIA RESEARCH

Wnt Signaling Promotes Reprogramming of Somatic Cells to Pluripotency

(2008) Alexander Marson et al.   Cell Stem Cell

Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics

(2008) A. C. Mita et al.   CLINICAL CANCER RESEARCH

Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors

(2008) H Konig et al.   LEUKEMIA

Optimizing Outcomes for Patients With Advanced Disease in Chronic Myelogenous Leukemia

(2008) Francis J. Giles et al.   SEMINARS IN ONCOLOGY